Moxalactam exists in two epimeric forms, R and S. The in vitro activity of these two epimers was compared with that of material available for clinical and laboratory use (R + S moxalactam). Generally, R moxalactam was twice as active as the S form. The stability of R + S moxalactam was studied at 37, 20, 4, and -20°C in buffer and serum. Only in serum at 37°C was there any appreciable loss of activity (half-life, 8 h). The stability of R and S epimers was studied separately, and the composition of the resulting equilibrium was investigated. At 37°C in serum, one-half of the excess of either R or S over the equilibrium mixture was converted into the equilibrium mixture in 1.5 h. The proportions of R to S in an equilibrium mixture in buffer were 50:50, but in serum they were 45:55. It is doubtful whether these differences in stability and activity will have any significant clinical importance.
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Moxalactam (LY127935, 6059S) is a broadspectrum oxa-f,-lactam (3) . During a pharmacological study on this compound (6), it was observed that high-performance liquid chromatographic analysis of samples and standards yielded a double peak. Information from Lilly Research Centre Limited, Windlesham, U. K., indicated that these peaks corresponded to the two epimers of moxalactam. These epimers are known as R and S moxalactam and correspond to the D and L of prior nomenclature. This study compares two important properties of these epimers, the antimicrobial activity and stability.
MATERIALS AND METHODS
The two epimners, R (potency, 773 ig/mg) and S (potency, ">85%"; taken as 90%) moxalactam, together with an R and S mixture (potency, 10 R) epimer is somewhat more active than the L (or S) epimer. In the case of carbenicillin, epimerization is too rapid to detect differences in activity. Both epimers of phenethicillin have similar activities. It has been postulated (1) that the reasons behind these differences in activity are that the more active epimer would mimic more closely the pentapeptide precursor of the cell wall.
In Table 2 the in vitro stability of R + S moxalactam is shown and expressed in terms of the half-life. Only in serum at 37°C was there any appreciable instability of the compound. At 4 and -20°C there was less than 10% loss of material in 100 h.
The stability of R and S moxalactam is expressed as the interconversion half-life, that is, the time taken for the percentage of excess (over the equilibrium mixture) of either the R or S epimer to be reduced by half. Each epimer was stable in that form at -20°C, and each was more stable at all temperatures in buffer solution rather than serum. In serum, the S forn converted to R + S more rapidly than did the R epimner. 
